Zurich Cantonal Bank
TBPH

Zurich Cantonal Bank’s Theravance Biopharma TBPH Stock Holding History

Zurich Cantonal Bank’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-868
Closed -$16.2K – 3398
2025
Q4 		$16.2K Buy
+868
New +$14.4K ﹤0.01% 2472

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Zurich Cantonal Bank's TBPH Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Theravance Biopharma (TBPH) stake by 4.5% in Q2 2026, buying an estimated $11.3K and bringing the position to 15,991 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #2225.

Zurich Cantonal Bank first reported a position in TBPH in Q2 2014 and has held it in 41 quarters since. The position peaked at $364K in Q2 2014. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Zurich Cantonal Bank held 15,991 shares of Theravance Biopharma worth $272K as of Q2 2026.
  • Zurich Cantonal Bank bought 682 Theravance Biopharma shares in Q2 2026, an estimated $11.3K.
  • Theravance Biopharma made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2225 holding.
  • Zurich Cantonal Bank first reported a position in Theravance Biopharma in Q2 2014 and has held it in 41 quarters since.
  • Zurich Cantonal Bank's Theravance Biopharma position peaked at $364K in Q2 2014.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.